Osaka, Japan

Takeshi Endoh

USPTO Granted Patents = 5 

 


Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Toyonaka, JP (2015)
  • Osaka, JP (2004 - 2017)

Company Filing History:


Years Active: 2004-2017

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations by Takeshi Endoh

Introduction

Takeshi Endoh is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of receptor antagonists. With a total of five patents to his name, Endoh's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Endoh has developed a triazine derivative and a pharmaceutical composition comprising the same. This invention provides a novel P2X and/or P2X receptor antagonist. The compound is represented by a specific formula, which includes various substituents. Another notable patent involves a heterocyclic derivative and a pharmaceutical composition that also exhibits a P2X and/or P2X receptor antagonistic effect. This composition is crucial for advancing treatments that target these receptors.

Career Highlights

Endoh is currently associated with Shionogi & Company Limited, a well-respected pharmaceutical company. His work at Shionogi has allowed him to focus on innovative drug development, contributing to the company's reputation for excellence in the pharmaceutical industry.

Collaborations

Throughout his career, Endoh has collaborated with notable colleagues, including Hiroyuki Kai and Takayuki Kameyama. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Takeshi Endoh's contributions to pharmaceutical innovations highlight his expertise and dedication to advancing medical science. His patents reflect a commitment to developing effective treatments that can benefit patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…